Find, compare & contact
Pegpleranib
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Pegpleranib API 1618657-13-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Pegpleranib. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Pegpleranib
- Synonyms:
- Cas Number:
- 1618657-13-8
- DrugBank number:
- DB06325
- Unique Ingredient Identifier:
- VER541H6NK
General Description:
Pegpleranib is a chemical compound identified by the CAS number 1618657-13-8. It is known for its distinct pharmacological properties and applications.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in macular degeneration and eye disorders/infections. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Pegpleranib functions by: E10030 is an aptamer based, anti-platelet-derived growth factor (PDGF) which inhibits PDGF-B with high specificity and affinity. E10030 may be efficacious in treating neovascular age-related macular degeneration when combined with a vascular endothelial growth factor A (VEGF-A) inhibitor. PDGF-B is implicated in vascular stability and function through its role in activating the recruitment of mural cells (pericytes) by endothelial cells to envelop the developing vasculature. Pericyte recruitment is part of the maturation process in blood vessel development and pericytes act as support cells for mature blood vessels. Neovascular age-related macular degeneration is a condition where new, extremely fragile blood vessels under the retina where they burst and cause damage to surrounding tissue, resulting in vision problems. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Pegpleranib is categorized under the following therapeutic classes: Pegylated agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Pegpleranib is a type of Platelet Aggregation Inhibitors
Platelet Aggregation Inhibitors are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the field of cardiology and thrombosis management. These inhibitors play a vital role in preventing platelet aggregation, a process responsible for the formation of blood clots. By inhibiting platelet aggregation, these APIs reduce the risk of arterial thrombosis, which can lead to severe cardiovascular events like heart attacks and strokes.
Platelet Aggregation Inhibitors primarily work by targeting specific receptors on platelet cells, thereby impeding their activation and subsequent aggregation. The most commonly utilized APIs in this category include acetylsalicylic acid (aspirin), clopidogrel, ticagrelor, and prasugrel. These drugs are available in various forms, such as tablets, capsules, and intravenous formulations, allowing flexibility in their administration.
The effectiveness of Platelet Aggregation Inhibitors lies in their ability to prevent platelets from adhering to each other and forming clots within blood vessels. This property is especially crucial in patients with a high risk of cardiovascular events, such as those with a history of heart disease, diabetes, or peripheral artery disease.
While Platelet Aggregation Inhibitors are generally safe and effective, they can also carry potential side effects, including bleeding complications. Therefore, their administration requires careful consideration of individual patient characteristics and risk factors.
In conclusion, Platelet Aggregation Inhibitors represent a significant category of pharmaceutical APIs used for the prevention of platelet aggregation and subsequent blood clot formation. By inhibiting this process, they contribute to the management and reduction of cardiovascular events, offering critical benefits to patients at risk.
